Myasthenia gravis (MG): investigational treatments

Tacrolimus

• This is especially effective if anti RyR antibodies are positive
• Adequate concentrations are essential for treatment response

Anti-human neonatal Fc receptor (FcRn) monoclonal antibodies

Anti C5 monoclonal antibodies

Anti CD20 monoclonal antibodies

Other investigational drugs

Other investigational interventions

References

1. Jordan A, Freimer M. Recent advances in understanding and managing myasthenia gravis. F1000Res 2018; 7. pii: F1000 Faculty Rev-1727.
2. Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies directed against b-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs 2019; 79:353-364. 
3. Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, Vidarsson G. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci 2021; 430:118074. 
4. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175:408-418.
5. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 2018; 11:1756285617749134.
6. And 27 more. Subscribe to see the full list

Related checklists

• Myasthenia gravis (MG) treatment: pyridostigmine
• Myasthenia gravis (MG) treatment: steroids
• Myasthenia gravis (MG): non-steroid immunosuppression: indications
• Myasthenia gravis (MG): non-steroid immunosuppression: agents
• Thymectomy for non-thymoma myasthenia gravis (MG)
• Myasthenia gravis (MG): rehabilitation
• Myasthenia gravis (MG) and anaesthesia